Cadrenal Therapeutics, Inc.
CVKD
$12.32
-$0.1618-1.30%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 9.33M | 7.88M | 6.75M | 4.92M | 4.14M |
Depreciation & Amortization | 6.70K | 6.80K | 1.90K | 2.10K | 2.30K |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 14.40M | 13.13M | 10.96M | 7.95M | 6.63M |
Operating Income | -14.40M | -13.13M | -10.96M | -7.95M | -6.63M |
Income Before Tax | -14.11M | -12.83M | -10.65M | -7.61M | -6.24M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -14.11 | -12.83 | -10.65 | -7.61 | -6.24 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -14.11M | -12.83M | -10.65M | -7.61M | -6.24M |
EBIT | -14.40M | -13.13M | -10.96M | -7.95M | -6.63M |
EBITDA | -14.39M | -13.13M | -10.96M | -7.94M | -6.63M |
EPS Basic | -8.69 | -9.06 | -8.54 | -7.05 | -5.88 |
Normalized Basic EPS | -5.43 | -5.66 | -5.33 | -4.41 | -3.68 |
EPS Diluted | -8.69 | -9.06 | -8.54 | -7.05 | -5.88 |
Normalized Diluted EPS | -5.43 | -5.66 | -5.33 | -4.41 | -3.68 |
Average Basic Shares Outstanding | 6.55M | 5.66M | 4.88M | 4.31M | 4.23M |
Average Diluted Shares Outstanding | 6.55M | 5.66M | 4.88M | 4.31M | 4.23M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |